Review of certain articles of the American society of bone and mineral research (ASMBR) annual congress 2019
https://doi.org/10.14341/osteo12466
Abstract
The annual congress of the American Society of Bone and Mineral Research (ASBMR) presents the most significant results among the basic and clinical research in the field of osteoporosis and other metabolic bone diseases. Professor of Medicine John Bilezikian, M.D., Columbia University College of Physicians and Surgeons New York, New York and Lynda F. Bonewald Ph.D. Director, Indiana Center for Musculoskeletal Health, Indianapolis, Indiana, every year present the most outstanding abstracts before the ASBMR. However, not all of these researches are relevant for Russia, as some of them relates to the epidemiology and pharmacoeconomics of osteoporosis specifically in the US. This review presents only a very limited selection of congress abstracts, combined on topics that seem relevant today.
About the Author
Zhanna E. Belaya
Endocrinology Research Centre
Russian Federation
Russian Federation
MD, PhD, Professor
References
1. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза // Проблемы Эндокринологии. - 2017. - Т. 63. - №6. - C. 392-426. [Mel’nichenko GA, Belaya ZE, Rozhinskaya LY, Toroptsova NV, Alekseeva LI, Biryukova EV, и др. Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problems of Endocrinology. 2017;63(6):392-426. (In Russ).] doi: https://doi.org/10.14341/probl2017636392-426.
2. Белова К.Ю., Ершова О.Б., Дегтярев А.А., и др. Система профилактики повторных переломов: первые итоги пилотной программы в рамках проекта «Прометей» в городе Ярославле // Остеопороз и остеопатии. - 2014. - Т. 17. - №2. - C. 3-6 [Belova KY, Yershova OB, Degtyarev AA, Belov MV, Gerasimov VO, Fedotov SY. Refracture prevention system: first results of a pilot program within the project «Prometheus» in Yaroslavl. Osteoporosis and Bone Diseases. 2014;17(2):3-6. (In Russ),] doi: https://doi.org/10.14341/osteo201423-6
3. Kristian Axelsson, Mattias Lorentzon, Dan Lundh, Helena Johansson, Michael Möller Implementation of Fracture Liaison Services in two Swedish hospitals was associated with reduced risk of recurrent clinical fractures in patients with osteoporotic fracture. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
4. María Belén Zanchetta, Fernando Silveira, Helena Salerni, Jose Zanchetta, Bisphophonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
5. Laura Dickens, Tamara Vokes Oral vs Intravenous Bisphosphonates for Preventing Bone Loss After Denosumab Discontinuation. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
6. Joy Tsai, Natalie David, Grace Sassana, Benjamin Leder. Zoledronic Acid Maintains Bone Mineral Density after Denosumab Administration (DATA-HD Extension). J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
7. Anne Sophie Sølling, Torben Harsløf, Bente Lomholt Langdahl Treatment with zoledronic acid subsequent to treatment with denosumab. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
8. David Kendler, Patricia Clark, Peter R Ebeling, Michael McClung, Yumie Rhee, Shuang Huang, Robert Kees Stad Subject Characteristics and Changes in Bone Mineral Density After Transitioning From Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
9. Белая Ж.Е., Bilezikian J.P., Ершова О.Б., и др. Возможности длительной терапии постменопаузального остеопороза: обзор результатов клинических исследований деносумаба и резолюция совета экспертов российской ассоциации по остеопорозу (РАОП) // Остеопороз и остеопатии. - 2018. - Т. 21. - №1. - C. 17-22. [Belaya ZE, Bilezikian JP, Ershova OB, et al. Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab. Osteoporosis and Bone Diseases. 2018;21(1):17-22. (In Russ).] doi: https://doi.org/10.14341/osteo9760.
10. Michelle McDonald, Pei Ying Ng, Weng Hua Khoo, Sindhu Mohanty, Mate Biro, Ryan Chai, Julian Quinn, Jessica Pettitt, Ya Xiao, Paul Baldock, Michael Rogers, Nathan Pavlos, Peter Croucher, Tri Phan Intravital imaging of osteoclasts in vivo reveals novel osteoclast fate which may underlie the therapeutic response to Denosumab withdrawal. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
11. Duncan Tourolle né Betts, Charles Ledoux, Daniele Boaretti, Mauricio Aguilera, Najma Saleem, Ralph Müller Denosumab 10 Year Simulation of Bone Remodeling In Human Biopsies. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
12. Cummings SR, Martin JS, McClung MR, et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N. Engl. J. Med. 2009;361(8):756-765. doi: https://doi.org/10.1056/NEJMoa0809493.
13. Fabrizio Pin, Lynda F. Bonewald, Andrea Bonetto Еffects of RANKL producing compared to non-RANKL producing tumors on muscle and bone. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
14. Steven Phu, Ebrahim Bani Hassan, Sara Vogrin, Ahmed Al Saedi, Ben Kirk, Gustavo Duque Effect of denosumab on falls, muscle strength and function in community dwelling older adults. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
15. Megan Weivoda, Tan Tock Seng, Elizabeth Atkinson, Josh Farr, Brianne Thicke, Ming Ruan, Amanda Tweed, Brittany Eckhardt, Louise McCready, Jennifer Geske, Robert Rizza, Adrian Vella, Aleksey Matveyenko, Moustapha Kassem, Thomas Andersen, Matthew Drake, Bart Clarke, Merry Jo Oursler, Sundeep Khosla Identification of novel factors involved in the coupling of bone resorption and bone formation in humans reveals RANKL/DPP4 as a new link between bone remodeling and energy metabolism. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
16. Mikkel Pretorius, Karolina Lundstam, Ansgar Heck, Kristin Godang, Kjersti Ringvoll Normann, Mikael Hellstøm, Jens Bollerslev Effect of Parathyroidectomy on Quality of Life: 10 Year Data from a Prospective Randomized Control Trial on Primary Hyperparathyroidism (the SIPH-study). J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
17. Lara Voss, Maira Nóbrega, Leonardo Bandeira, Pedro Rocha-Filho. Impaired Cognitive Function in Normocalcemic Primary Hyperparathyroidism. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
18. Yosef Caraco, Nariman Saba Khazen, Yonit Marcus, Auryan Szalat, Liana Tripto-Shkolnik, Vanessa Roach, Elena Segal, Gloria Tsvetov, Merav Fraenkel, Gregory Burshtien, Arthur Santora, Hillel Galitzer, Ariel Rothner, Anke Hoppe, Phillip Schwartz, Sofia Ish-Shalom An Evaluation of the Pharmacodynamic Effects of an Oral hPTH(1-34) formulation in Patients with Hypoparathyroidism. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
19. Mamedova E, Dimitrova D, Przhiyalkovskaya E, et al. Non-lethal Raine Syndrome in a Middle-Aged Woman Caused by a Novel FAM20C Mutation. Calcif. Tissue Int. 2019;105(5):567-572. doi: https://doi.org/10.1007/s00223-019-00599-w.
20. Raine J, Winter RM, Davey A, Tucker SM. Unknown syndrome: microcephaly, hypoplastic nose, exophthalmos, gum hyperplasia, cleft palate, low set ears, and osteosclerosis. J. Med. Genet. 1989;26(12):786-788. doi: https://doi.org/10.1136/jmg.26.12.786.
21. Elalaoui SC, Al-Sheqaih N, Ratbi I, et al. Non lethal Raine syndrome and differential diagnosis. Eur. J. Med. Genet. 2016;59(11):577-583. doi: https://doi.org/10.1016/j.ejmg.2016.09.018.
22. Rolvien T, Kornak U, Schinke T, et al. A novel FAM20C mutation causing hypophosphatemic osteomalacia with osteosclerosis (mild Raine syndrome) in an elderly man with spontaneous osteonecrosis of the knee. Osteoporos. Int. 2018;30(3):685-689. doi: https://doi.org/10.1007/s00198-018-4667-6.
23. Калинченко Н.Ю., Голоунина О.О., Гребенникова Т.А., и др. Опыт клинического применения асфотазы альфа у молодого пациента с детской формой гипофосфатазии // Остеопороз и остеопатии. - 2019. - Т. 22. - №1. - C. 24-29. [Kalinchenko NY, Golounina OO, Grebennikova TA, et al. Clinical application experience of asfotase alfa for a young patient with childhood hypophosphatasia. Osteoporosis and Bone Diseases. 2019;22(1):24-29. (In Russ).] doi: https://doi.org/10.14341/osteo10136.
24. Zhanna Belaya, Natalia Kalinchenko, Olga Golounina, Tatiana Grebennikova, Anatoliy Tiulpakov, Galina Melnichenko Hypophosphatasia treatment with recombinant human TNSALP in an 18-year-old patient. J. Bone Miner. Res. 2019;34(S1):S1-S442. doi: https://doi.org/10.1002/jbmr.3936.
Review
For citations:
Belaya Zh.E. Review of certain articles of the American society of bone and mineral research (ASMBR) annual congress 2019. Osteoporosis and Bone Diseases. 2019;22(4):12-18. (In Russ.) https://doi.org/10.14341/osteo12466
Views:
1117
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
